相关实验视频

Updated: Jun 22, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

超越抗PD-1/PD-L1:改善免疫检查点抑制剂对三阴性乳腺癌的反应

Kennady K Bullock¹, Ann Richmond¹

¹Department of Pharmacology, School of Medicine, Vanderbilt University, Nashville, TN 37232, USA.

|June 27, 2024

概括

改善三阴性乳腺癌 (TNBC) 的免疫疗法需要更好的患者选择和组合疗法. 研究人员正在探索超越反编程细胞死亡蛋白-1 (anti-PD-1) 的新策略,以增强持久的缓解.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
癌症研究癌症研究

背景情况:

三重阴性乳腺癌 (TNBC) 治疗历史上依赖于化疗和手术.
反编程细胞死亡蛋白-1 (anti-PD-1) 疗法提供了突破性进展,但很少有TNBC患者受益.
用抗PD-1治疗的TNBC患者的持久缓解率仍然有限,需要改进策略.

研究的目的:

审查用于增强免疫检查点抑制 (ICI) 响应率的概念策略.
探索改善患者选择抗PD-1疗法的方法.
确定TNBC的协同向疗法和新型免疫疗法方法.

主要方法:

对TNBC中抗PD-1反应和耐药性的生物标志物的当前文献的综述.
分析现有的向疗法 (例如PI3K/AKT,RAS/MAPK/ERK抑制剂) 与ICI的协同作用.
探索TNBC的PD-1轴抑制之外的新兴免疫疗法策略.

主要成果:

在TNBC中抗PD-1反应的最佳生物标志物可能是多方面的.
涉及PI3K/AKT或RAS/MAPK/ERK通路抑制剂的组合疗法显示了与ICI的潜在协同作用.
目前正在进行的研究正在确定TNBC的新型免疫治疗点.

结论:

在TNBC中提高ICI疗效需要多方面的方法.
改善患者分层和组合疗法对于最大化抗PD-1益处至关重要.
对新型免疫疗法进行进一步的研究是必要的TNBC治疗.

关键词:

在PD-1中使用PD-1.在PD-L1中.在PI3K/AKT中使用.在RAS/MAPK/ERK.免疫检查点抑制抑制免疫检查点抑制三重阴性乳腺癌是什么

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...